- Home
- COEP vs CVKD Comparison
COEP vs CVKD Comparison
Compare COEP & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- CVKD
- Stock Information
- Founded
- COEP 2017
- CVKD 2022
- Country
- COEP United States
- CVKD United States
- Employees
- COEP N/A
- CVKD N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- COEP Health Care
- CVKD Health Care
- Exchange
- COEP Nasdaq
- CVKD Nasdaq
- Market Cap
- COEP 27.4M
- CVKD 29.5M
- IPO Year
- COEP N/A
- CVKD 2023
- Fundamental
- Price
- COEP $9.47
- CVKD $12.71
- Analyst Decision
- COEP
- CVKD Strong Buy
- Analyst Count
- COEP 0
- CVKD 1
- Target Price
- COEP N/A
- CVKD $32.00
- AVG Volume (30 Days)
- COEP 38.0K
- CVKD 35.8K
- Earning Date
- COEP 08-15-2025
- CVKD 08-06-2025
- Dividend Yield
- COEP N/A
- CVKD N/A
- EPS Growth
- COEP N/A
- CVKD N/A
- EPS
- COEP N/A
- CVKD N/A
- Revenue
- COEP $62,874.00
- CVKD N/A
- Revenue This Year
- COEP N/A
- CVKD N/A
- Revenue Next Year
- COEP N/A
- CVKD N/A
- P/E Ratio
- COEP N/A
- CVKD N/A
- Revenue Growth
- COEP N/A
- CVKD N/A
- 52 Week Low
- COEP $2.31
- CVKD $5.70
- 52 Week High
- COEP $13.70
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- COEP 62.24
- CVKD 49.98
- Support Level
- COEP $7.25
- CVKD $11.00
- Resistance Level
- COEP $9.90
- CVKD $13.56
- Average True Range (ATR)
- COEP 0.63
- CVKD 1.15
- MACD
- COEP 0.26
- CVKD 0.25
- Stochastic Oscillator
- COEP 85.62
- CVKD 80.97
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.